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ABSTRAKT  
Univerzita Karlova v Praze  
Farmaceutická fakulta v Hradci Králové  
Katedra farmakologie a toxikologie  
Kandidát:  Dagmar Škoricová 
Školitelé:  Prof. Dr. Rohini Kuner  
Doc. PharmDr. Petr Pávek, Ph.D.  
Název diplomové práce: Stanovení role lysofosfatidylinositolu, GPR55 agonisty, u 
mechanicky způsobené bolesti. 
Nedávné studie naznačují, že sirotčí receptor GPR55 (receptor spojený s G-
proteinem 55), který je aktivován několika různými kanabinoidními ligandy a také 
lysofosfolipidem L-α-lysofosfatidylinositolem (LPI), může být nový kanabinoidní 
receptor. 
GPR55 je podle studií exprimován na senzorických neuronech a u GPR55 
deficientních myší byla prokázána snížená mechanická hypersenzitivita v modelech 
zánětlivé a neuropatické bolesti. To společně naznačuje možnou pronocicepční roli 
receptoru GPR55. Bylo také zjištěno, že LPI je vylučován ve velkém množství z 
nádorových tkání. To nás vedlo k domněnce, že LPI uvolněné z rakovinových buněk 
může vést k sensitizaci nociceptorů a tím k rakovinou-indukované bolesti. 
Cílem této práce bylo zjistit úlohu LPI v onkologické, mechanicky indukované bolesti 
a její možný mechanismus. Zjistili jsme, že neurony ganglií zadních kořenů míšních jsou 
in vitro přímo aktivované LPI. Také jsme zjistili, že periferní aplikace LPI u myší vede k 
mechanické přecitlivělosti v závislosti na dávce, aniž by byl vyvolaný zánět, 
demyelinizace nebo extravazace. 
Tyto výsledky naznačují možnou roli LPI-GPR55 signalní dráhy v rakovinou vyvolané 
bolesti. Blokování GPR55 signální dráhy specifickými ligandy by tedy mohlo sloužit jako 
potenciální terapeutická strategie k léčbě onkologické bolesti.  
 
 
ABSTRACT 
Charles University in Prague  
Faculty of Pharmacy in Hradec Králové  
Department of Pharmacology and Toxicology  
Candidate:  Dagmar Škoricová 
Supervisors:  Prof. Dr. Rohini Kuner 
Doc. PharmDr. Petr Pávek, Ph.D. 
Title of diploma thesis: Dissecting the role of GPR55 agonist lysophosphatidylinositol 
in mechanically evoked pain 
Recent studies have suggested that the orphan receptor GPR55 (G-protein coupled 
receptor 55) is possibly a novel cannabinoid receptor activated by multiple different 
cannabinoid ligands and also by the lysophospholipid L-α-lysophosphatidylinositol 
(LPI).  
GPR55 is reported to be expressed on sensory neurons and mice lacking GPR55 
were shown to have reduced mechanical hypersensitivity in inflammatory and 
neuropathic pain models, suggesting a pronociceptive role of GPR55. LPI was found to 
be secreted in large quantities from varieties of cancer tissue. These facts led us to 
speculate that LPI released from cancer cells could sensitize nociceptors and thereby 
lead to cancer-induced pain. 
The aim of the study was to investigate the role of LPI in cancer induced, 
mechanically evoked pain and its possible underlying mechanism. We found that the 
dorsal root ganglion neurons are directly activated by LPI in vitro. We also found that 
LPI injected in the periphery leads to a mechanical hypersensitivity in mice in a dose 
dependent manner without eliciting any inflammation, demyelination or 
extravasation. 
These results indicate a possible role of LPI-GPR55 signaling pathway in cancer induced 
pain. Blocking of GPR55 signaling with specific ligands might therefore serve as a 
potential therapeutic strategy to treat cancer induced pain.  
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1 INTRODUCTION 
The sensation of pain is one of the crucial physiological functions of the nervous 
system as it is a response of an organism to actual or potential harm in order to avoid 
tissue damage. However, sustained or chronic pain can result in secondary symptoms 
such as anxiety or depression associated with decrease of the quality of life. This kind 
of pain no longer has a protective role and should be considered a disease itself rather 
than just a symptom.  
Demographical studies concerning pain prevalence vary widely, mainly depending 
on the methodology and also because pain is a subjective phenomenon with no 
available standard clinical tool, so the studies rely on self-reported measures of pain. 
All studies, however, leave no question that persisting pain occurs in high rates in 
people of all ages.  
In general, 33 % of European population has already experienced severe pain in 
some episode of the life, whereas 18 % of European people reports ongoing middle to 
severe chronic pain condition. The prevalence of pain at the time of cancer diagnosis is 
estimated to be approximately 50 % in the early stage, increasing to 75 % at advanced 
stages, while cancer patients experience pain as the result not only of the disease, but 
also of its treatment, surgery, diagnosis or unrelated causes (www.iasp-pain.com). 
The impact and behavioral course of painful conditions varies across individuals, 
whereas the common disruptive pattern concerning psychological distress, depression 
or anxiety disorders interfere with their normal activity and cause severe social 
problems. 
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2 PAIN 
There are various definitions of pain, whereas the most accurate seems to be the 
definition of The International Association for the Study of Pain (IASP), which defines 
pain as an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage or both (www.iasp-
pain.org). 
While nociceptive pain is a protective physiological component of the normal 
nervous system, pathological pain typically results from damage to the nervous system 
(neuropathic pain) or its abnormal functioning (dysfunctional pain). Neuropathic pain 
also commonly occurs as a secondary symptom in diseases, such as diabetes, cancer or 
herpes zoster infection and it is often characterized as stimulus-independent 
persistent pain or abnormal sensory sensation of pain (Basbaum 1999). A special class 
of pain, inflammatory pain, is associated with a tissue damage and infiltration of cells 
contributing to immune response (Woolf) (Figure 2.1). 
In the cancer population, neuropathic pain often results from nerve compression, 
direct neoplastic invasion of the peripheral nerves or spinal cord, or the neuropathy is 
related to the treatment (Farrar and Portenoy 2001), but it can also be caused by 
ischemia or proteolysis that injures the sensory and sympathetic nerve fibers (Usunoff 
et al. 2006). Moreover, tumors produce a variety of factors that sensitize or directly 
excite nociceptors, causing pain sensation (Mantyh et al. 2002). 
 Signs and symptoms of pathological pain differ in disease and patient, but they 
share certain clinical characteristics: continuous pain, usually of a dull and burning 
character, paroxysmal pain (shooting, lancinating), lowered pain threshold to various 
mechanical or thermal, noxious or non-noxious stimuli (Usunoff et al. 2006). 
Somatic sensibility is mediated by different types of receptors distributed 
throughout the body. Each of these receptors is morphologically and molecularly 
specialized to selectively respond to the specific type of stimuli. Periphery receptors 
recognize discriminative touch (size, shape, and texture of objects), proprioception 
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(position and movement of the body), nociception (tissue damage or chemical 
irritation), and temperature sense (warmth and cold) (Kandel et al. 2000).  
 
Figure 2.1. Pain classification (Woolf) (A) Nociceptive pain with protective function.                         
(B) Inflammatory pain with contribution of immune system.                                                                    
(C) Pathological pain associated with nerve damage or abnormal functioning. 
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Each of the modalities is mediated by different receptors and pathways to the 
brain. However, all these receptors are part of the periphery terminals of sensory 
neurons, which cell bodies are located in the dorsal root ganglia for the body and 
trigeminal ganglia for the facial area (Kandel et al. 2000).  
2.1 Nociceptors and nociception 
Nociceptors, a term first mentioned by Sherrington in 1906, are the primary sensory 
neurons that respond selectively to stimuli that can cause tissue damage (Sherrington 
1906). Nociceptors have four major functional components, the peripheral terminal, 
the axon, the cell body and the central terminal (Woolf and Ma 2007) (Figure 2.2.). 
Nociceptors, together with other sensory neurons belong to the family of pseudo-
unipolar cells with single axon that bifurcates into two branches. One projecting to the 
central nervous system and one projecting to the periphery as free nerve endings, 
where it transduces external stimuli and initiates action potentials. Nociceptive 
primary afferent axons terminate in the dorsal horn of the spinal cord, which is the site 
of the first synapse on nociceptive second order neurons in spinothalamic and 
spinobrachial ascending pathways conveying to the brain sensory information 
underlying conscious perception of pain (Kandel et al. 2000).  
 
 
Figure 2.2. The morphology of a dorsal root ganglion cell (Kandel et al. 2000) 
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Peripheral somatosensory neurons contain several different types of axons that 
carry sensory information, which divides cutaneous nociceptors into two major classes 
(Kuner 2003). Medium diameter myelinated Aδ mechanoreceptors, whose stimulation 
leads to fast, pricking pain and unmyelinated C-nociceptors, whose stimulation evokes 
sensation of slow, burning or dull pain (Basbaum et al. 2009).  
Aδ fibers are high-threshold nociceptors that respond to noxious mechanical 
stimuli, whereas Aα involved in proprioception and Aβ cutaneous mechanoreceptors, 
normally do not conduct noxious stimuli. Aδ fibers respond to painful stimuli caused by 
sharp objects that penetrate, squeeze, or pinch the skin (Meyer et al. 2006) and they 
are further divided according to their differential responsiveness to intense heat and 
their sensitization ability (Julius and Basbaum 2001).  
C fibers are slowly conducting afferents present in the majority of sensory neurons 
in peripheral nervous system, but not all of them are involved in nociception. Some 
also mediate pleasant touch or respond to stroking of the hairy skin (Olausson et al. 
2008). Most C-fiber nociceptors are polymodal, responding nonselectively to noxious 
thermal, mechanical and chemical stimuli (Julius and Basbaum 2001).  
Silent nociceptors are a special class of unmyelinated afferents, which are heat 
responsive, but normally mechanically insensitive, however, they become 
mechanically sensitive only when sensitized by tissue injury (Schmidt et al. 1995).  
Primary afferents release a variety of chemical mediators, but the principal 
excitatory neurotransmitter is amino acid glutamate. Glutamate evokes fast synaptic 
potentials in dorsal horn neurons by activating several types of postsynaptic glutamate 
receptors, such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors, N-methyl-D-aspartase (NMDA) receptors and metabotropic glutamate 
receptors (mGluRs) (Kuner 2003). The primary afferent fibers of nociceptive neurons 
also elicit slow excitatory postsynaptic potentials in dorsal horn neurons by releasing 
various peptide neurotransmitters, such as substance P and calcitonin gene-related 
peptide (CGRP). They are involved in the response to intense stimulation of peripheral 
nerves as they contribute to the spread of oedema by their vasodilatating effect and to 
sensitization of nociceptors by releasing of histamine from mast cells. Moreover, 
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neuroactive peptides also appear to enhance and prolong the actions of glutamate and 
their levels are significantly increased in persistent pain conditions, suggesting that 
they play an important role in developing of neuropathic pain states (Kandel et al. 
2000). 
2.2 Sensitization 
In pathological situations, repeated activation of nociceptors can lead to various 
states of abnormal pain called sensitization (Nestler et al. 2009).  
Sensitization of nociceptors after injury or inflammation is induced by chemical 
mediators released by the damaged cells and tissues, such as prostaglandins, 
leukotrienes, cytokines, chemokines, growth factors, bradykinin, histamine, 
acetylcholine, serotonin, substance P and others. They all act to decrease the 
threshold for activation of nociceptors which results in excessive response to noxious 
stimuli – hyperalgesia.  Primary hyperalgesia occurs in the damaged area, whereas 
secondary hyperalgesia occurs when also surrounding area becomes sensitive (Kuner 
2003). Some substances, however, directly activate nociceptors leading to the 
sensation of pain in response to normally innocuous stimuli, referred to as allodynia 
(Kandel et al. 2000).   
Heightened sensitivity presumably serves the adaptive purpose of leading an 
organism to protection of the injured area in the short term, but it is a major cause of 
clinically significant pain if it persists. Sensitization of primary nociceptors may lead to 
long-term changes in second-order neurons within the dorsal horn called central 
sensitization. It is a form of excessive excitatory synaptic responses in nociceptive 
neurons, which leads to an increased gain of the pain transmission system and pain 
hypersensitivity (Nestler et al. 2009). 
The combination of peripheral and central sensitization underlies neuropathic pain, 
resulting in chronic allodynia, hyperalgesia, and spontaneous pain (Nestler et al. 2009). 
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2.3 G-protein-coupled receptors (GPCRs)  
Primary afferent somatosensory neurons possess a rich diversity of ligand-gated 
ionotropic, metabotropic and tyrosine kinase receptors. Many mediators produced 
during pain and inflammation, such as bradykinin, serotonin and prostaglandins, act 
via G-protein-coupled receptors (GPCRs). GPCRs are the plasma membrane receptors 
with seven transmembrane domains and a cytoplasmic domain. The cytoplasmic 
domain interacts with an intracellular heterotrimeric guanine nucleotide regulatory 
protein (G-protein) consisting of three subunits (α, β and γ). Subsequent  biochemical 
response depends on the type of α subunit that is activated. Gs/q stimulates, whereas 
Gi/o inhibits the activity of various enzymes (adenylate cyclases, guanylate cyclases, 
phospholipases, Ras etc..) leading to increase of level of diffusible second messengers, 
such as cyclic adenosine monophosphate (cAMP), diacylglycerol or inositol 
polyphosphate. G-proteins can also directly influence ion channels. The subsequent 
biochemical cascade leads to phosphorylation of cell proteins or mobilization of Ca2+ 
ions from intracellular stores (Strader et al. 1995; Kandel et al. 2000) (Figure 2.3.). 
 
Figure 2.3. Diversity of  G-protein coupled receptor signal transduction (Dorsam and Gutkind 
2007) 
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2.3.1 Cannabinoid receptors 
Two metabotropic cannabinoid receptors, CB1 and CB2 have been identified since 
1988, as the receptors through which cannabinoids (endogenous, plant or synthetic 
ligands) exert their effect (Devane et al. 1988). They are both Gi/o-coupled and their 
activation leads to inhibition of cAMP production via adenylate cyclase and activation 
of mitogen-activated protein kinase (MAPK) (extracellular-regulated protein kinase-
ERK). This signal transduction pathway leads to phosphorylation of critical amino acid 
residues on the intracellular surfaces (Ryberg et al. 2007). 
CB1 receptors are predominantly expressed in the CNS and by primary afferent 
neurons in peripheral nervous system and they are mainly involved in attenuation of 
synaptic transmission (Howlett 2002). Distribution of CB2 receptor is restricted to the 
cells of the immune system including glia, with particularly high levels in B cells and 
natural killer cells (Galiegue et al. 1995). Therefore, CB2 receptors are implicated in the 
regulation of inflammatory reactions and immune response as they are known to 
modulate cytokine release (Pertwee et al.). They are widely distributed along the pain-
regulatory circuits, which makes them potential target for therapy of different pain 
states.  
2.3.1.1 Cannabinoids 
Cannabinoids have significant antinociceptive efficacy, which has been used for 
centuries  for therapy of pain (Walker and Huang 2002), but the problem of physical 
and psychological side effects in the same dose range as that for analgesia limits their 
use as analgetics (Malan et al. 2003). 
Cannabinoids are a chemically heterogeneous group divided into three categories: 
the endocannabinoids, the phytocannabinoids and the synthetic compounds with 
cannabinoid-like activity. Cannabis sativa contains more than 60 phytocannabinoids, 
whereas the most abundant constituents include Δ9-tetrahydrocannabinol (THC), 
cannabidiol (CBD) and cannabinol (CBN). THC is thought to mediate its psychoactive 
and addictive properties mainly through neuronal CB1 receptors (Hall and Solowij 
1998), whereas CBD and CBN are not psychoactive and act mostly on CB2 receptors 
(Ross 2009). The antinociceptive effect of cannabinoids is mediated by suppression of 
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nociceptive transmission observed in behavioral studies using  thermal, mechanical 
and chemical noxious stimulation (Walker and Huang 2002). 
The identification of cannabinoid receptors expressed in mammalian tissues was 
followed by an intensive search for their endogenous ligands, which revealed the 
family of natural cannabinoid agonists – endocannabinoids (Devane et al. 1992; 
Sugiura et al. 1995). Their physiological role is still not well understood, but 
experiments with cannabinoid receptors deficient mice (Ledent et al. 1999; Zimmer et 
al. 1999; Buckley et al. 2000) suggest that their function is more modulatory rather 
than primary physiological. The processes influenced by endocannabinoids include 
cognition and memory, motor coordination, temperature homeostasis and sleep. The 
endocannabinoid system is also involved in the pathophysiology of obesity, 
osteoporosis, addiction, mental illness, neuropathic and inflammatory pain, 
cardiovascular disorders and liver diseases (Ross 2009). 
There are recently known a couple of endogenous ligands for CB receptors, whereas 
the most studied are anandamide (N-arachidonoylethanolamine, AEA) and 2-
arachidonoyl glycerol (2-AG) (Sugiura and Waku 2002). 
2.3.2 GPR55 
Studies performed with CB1 and CB2 deficient mice revealed circumstantial 
evidence for the existence of further cannabinoid receptors or subtypes (Howlett et al. 
2002; Begg et al. 2005; Mackie and Stella 2006). GPR55 showed the ability to interact 
and to be modulated by a variety of endogenous and exogenous cannabinoid ligands 
(Mackie and Stella 2006) and it has recently been classified as a putative third 
cannabinoid receptor (Ryberg et al. 2007). However, there are still some questions 
concerning this assignment and GPR55 pharmacology remains controversial. 
GPR55 is a seven transmembrane GPCR highly expressed in large-diameter DRG 
neurons (Lauckner et al. 2008), brain, lymphoid organs, immune cells, endothelial cells,  
osteoclastes and osteoblastes, which suggests that GPR55 plays a role in these tissues 
known to respond also to cannabinoids (Sharir and Abood). However, exact 
physiological or pathophysiological significance of this receptor remains elusive, but 
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regulation of both inflammatory and neuropathic pain seems to be one of its potential 
role, while experiments with GPR55 deficient mice revealed that these mice failed to 
develop mechanical hyperalgesia in models of inflammatory and neuropathic pain. 
Moreover, the levels of anti-inflammatory cytokines have increased as compared with 
wild-type animals (Staton et al. 2008).  
2.3.2.1 LPI (L-α-lysophosphatidylinositol) 
LPI is a bioactive lipid belonging to a family of lysophospholipids, which are 
molecularly diverse structures composed of various lengths of acyl chains containing 
saturated, monosaturated or polyunsaturated fatty acid at either sn-1 or sn-2 position. 
2-arachidonoyl-sn-glycero-3-phosphoinositol seems to have the greatest biological 
activity towards GPR55 compared to LPI species containing other fatty acyl groups 
(Oka et al. 2009) (Figure 2.4.). 
 
 
Lysophosphatidylinositol 
 
2-arachidonoyl-sn-glycero-3-phosphoinositol 
 
Figure 2.4. Chemical structures of lysophosphatidylinositol and 2-arachidonoyl-sn-glycero-3-
phosphoinositol, GPR55 lysophospholipid agonists 
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LPI induces stimulation of [35S]GTPγS-binding to G-proteins (agonist-induced GDP-
GTP exchange as an indicator of receptor activation), indicating that it exerts its effects 
via a G-protein-coupled apparatus. LPI was recently reported to be a GPR55 
endogenous ligand (Oka et al. 2007). 
Stimulation of GPR55 by LPI is known to activate Gα12, Gα13 or Gq proteins and to 
induce rapid phosphorylation of the extracellular signal-regulated kinase (ERK 1/2) in 
transiently or stably GPR55-expressing HEK293 cells (Henstridge et al.; Oka et al. 2007). 
Furthermore, LPI increases intracellular free calcium concentration possibly in the 
tissue-dependant manner, which as a consequence activates NFAT. (Henstridge et al.; 
Lauckner et al. 2008; Henstridge et al. 2009). NFAT as a key molecular target for GPR55 
then binds DNA and regulates the transcriptional activity of a number of genes (Im and 
Rao 2004). 
LPI is one of the key signaling intermediates that controls diverse aspects of cellular 
functions (Henstridge et al. 2009), but except for its physiological functions it was also 
found to contribute to cell growth of certain tumors. This mitogenic activity of LPI was 
demonstrated by several investigators (Falasca and Corda 1994; Falasca et al. 1998), 
finding that it is mediated by GPR55 receptor expressed in prostate and ovarian cancer 
cell line (Pineiro et al.). Blocking of GPR55 or its downregulation inhibits tumor cell 
proliferation, which indicates that LPI could constitute a novel cancer biomarker and 
GPR55 a potential therapeutic target for cancer treatment (Andradas et al.).  
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3 AIM OF THE WORK 
As this study is a part of a bigger project dissecting the role of LPI-GPR55 pathway in 
peripheral sensitization in pain states, the primary focus of this thesis is: 
 
1. To investigate whether bioactive phospholipid LPI can directly activate neurons of 
the dorsal root ganglion. 
2. To study if peripheral application of LPI leads to mechanical hypersensitivity in 
mice. 
3. To determine whether the mechanical hypersensitivity caused by LPI is mediated 
by 
a. inflammation 
b. extravasation 
c. demyelination 
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4 MATERIALS 
4.1 Animals 
All animals in this study were used according to the ethical guidelines of the local 
governing body. Animals were maintained with food and water ad libitum under 12-
hour light/dark cycle. All behavioral experiments were done in 2-3 months old, awake, 
unrestrained, age-matched, male or female mice (C57/Bl6). 
4.2 Materials 
Butterfly needle (BD microlance; BD Bisciences, GE) 
Carbon dioxide tank (Air Liquide Medical GmbH; Düsseldorf, GE) 
Coverslips (Medite GmbH; Brugdorf, GE) 
Falcon tubes 15 ml, 50 ml (Sarstedt AG & Co.; Nümbrecht, GE) 
Glass pipettes (Axon Labortechnik GmbH; Kaiserslautern, GE) 
Hamilton syringe (Hamilton Bonaduz AG; Bonaduz, Switzerland) 
Insulin syringe (BD finulane; BD Bisciences, GE) 
Microscope slides (NeoLab Migge Laborbedarf-Vertriebs GmbH; Heidelberg, GE) 
Microtube 1.5 ml (Sarstedt AG & Co.; Nümbrecht, GE) 
Mini trans-blot cell and Electrophoresis module (Mini-PROTEAN Tetra system) (Bio-Rad 
Laboratories GmbH; München, GE) 
Nitrocellulose transfer membrane (Whatman GmbH; Dassel, GE) 
Pipette (Gilson, Inc.; Middleton, WI, USA) 
Pipette boy – neoAccupette (Wager & Munz GmbH; München, GE) 
Pipette tips (Greiner bio-one GmbH; Frickenhausen, GE) 
Radiographic cassette (Dr.Goos-Suprema GmbH; Heidelberg, GE) 
Serological pipette 5 ml, 10 ml, 25 ml (Sarstedt AG & Co.; Nümbrecht, GE) 
Suture material Marlin® (Catgut GmbH; Markeneukirchen, GE) 
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Tissue culture dishes (Becton Dickinson Labware; Le Pon de Claix, France) 
Tissue freezing medium (R. Jung GmbH; Nußloch, GE) 
Von Frey Hairs - with grid (Ugo Basile; Italy) 
X-Ray film (FujiFilm Europe GmbH; Düsseldorf, GE)  
4.3 Instruments 
Centrifuge (Kendro Laboratory Products GmbH; Osterode, GE) 
CO2 Incubator (Thermo Fisher Scientific Inc.; Egelsbach, GE) 
Freezer -80°C (Haraeus Sepatech GmbH; Osterode, GE) 
Homogenizer (PRO Scientific Inc.; Oxford, CT, USA) 
Hood (Thermo Electron LED GmbH; Langenselbold, GE) 
Leica cryotome CM 3050 S (Leica Microsystems GmbH; Wetzlar, GE) 
Microscope Leica DM LS2 (Leica Microsystems GmbH; Wetzlar, GE) 
Nanodrop (Peqlab Biotechnologie GmbH; Erlangen; GE) 
Plantar Test - Hargreaves Apparatus (Ugo Basile; Italy) 
Power supply (Buddeberg GmbH; Mannheim, GE) 
Surgical tools (forceps, scissors, scalpels) (Fine Science Tools GmbH, Heidelberg, GE) 
Syringes (BD Syringe; BD Bisciences, GE) 
Syringe needle (BD microlance; BD Bisciences, GE)  
Thermomixer (Eppendorf AG; Hamburg, GE) 
Vortex machine (IKA® Werke GmbH & Co. KG; Staufen, GE) 
X-Ray film processor (PROTEC Medizintechnik GmbH & Co. KG; Oberstenfeld, GE) 
4.4 Chemicals 
All used chemicals were in the highest purity. 
2-mercaptoethanol (Carl Roth GmbH & Co. KG; Karlsruhe, GE) 
2-propanol or isopropanol (Merck KGaA; Darmstadt, GE) 
Acetic acid anhydrous (Merck KGaA; Darmstadt, GE) 
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Acryl-bisacrylamide mix – Rotiphorese Gel 30 (Carl Roth GmbH & Co. KG; Karlsruhe,  
GE) 
APS (Grüssing GmbH; Filsum, GE) 
Bromophenol Blue (Waldeck GmbH & Co. KG; Münster, GE) 
BSA - Albumin fraktion V (Carl Roth GmbH & Co. KG; Karlsruhe, GE) 
CFA (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
D(+)- Saccharose (Carl Roth GmbH & Co. KG; Karlsruhe, GE) 
DTT (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
EDTA (AppliChem GmbH; Darmstadt, GE) 
Ethanol 99% (Merck KGaA; Darmstadt, GE) 
Evans blue (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Fast green dye (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Formamide (Mallinckrodt Baker, Inc; Phillipsburg, NJ, USA) 
FBS (Invitrogen GmbH; Darmstadt, GE) 
Formalin, 10% Neutral Buffered - 4% PFA (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Glycerol anhydrous (AppliChem GmbH; Darmstadt, GE) 
Glycin (AppliChem GmbH; Darmstadt, GE) 
H2O2 30% (Carl Roth GmbH & Co. KG; Karlsruhe, GE) 
HCl fuming 37% (Merck KGaA; Darmstadt, GE) 
Histamine (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Horse serum (Invitrogen GmbH; Darmstadt, GE) 
Chloroform (VWR International GmbH; Darmstadt, GE) 
Isoflurane (Baxter Deutschland GmbH; Heidelberg, GE) 
KCl (AppliChem GmbH; Darmstadt, GE) 
KH2PO4 (Grüssing GmbH; Filsum, GE) 
LPI (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Methanol (Merck KGaA; Darmstadt, GE) 
Molecular weight marker – Protein ladder #1811 (Fermentas GmbH; St. Leon-Rot, GE) 
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Mowiol 4-88 (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Na2HPO4.2H2O (AppliChem GmbH; Darmstadt, GE) 
NaCl (VWR International GmbH; Darmstadt, GE) 
Nerve growth factor (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
NFDM – Milk powder (Carl Roth GmbH & Co. KG; Karlsruhe, GE) 
Nonidet P40 (Fluka Chemie AG; Buchs, Schwitzerland) 
Percoll (GE Healthcare Bio – Sciences AB; Uppsala, Sweden) 
Phosphatase inhibitor (Roche Diagnostics GmbH; Mannheim, GE) 
Poly-L-Lysine 0.1% (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Ponceau S (AppliChem GmbH; Darmstadt, GE) 
PP2 (Merck KgaA; Darmstadt, GE) 
Protease inhibitor (Roche Diagnostics GmbH; Mannheim, GE) 
SDS (Serva Electrophoresis GmbH; Heidelberg, GE) 
Sodium borate (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Sodium desossicolate (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Sodium orthovanadate (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
TEMED (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Toluidine blue (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Tris base (Carl Roth GmbH & Co. KG; Karlsruhe, GE) 
Triton X-100 (Merck KGaA; Darmstadt, GE) 
Trypsin inhibitor (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Tween 20 (Carl Roth GmbH & Co. KG; Karlsruhe, GE) 
Xylene (Grüssing GmbH, GE) 
4.5 Enzymes 
Collagenase (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
DNAse (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
Trypsin (Sigma-Aldrich Chemie GmbH; Steinheim, GE) 
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4.6 Mediums 
DMEM (Gibco, Invitrogen GmbH; Darmstadt, GE) 
DPBS 10x (Gibco, Invitrogen GmbH; Darmstadt, GE) 
F12 (Gibco, Invitrogen GmbH; Darmstadt, GE) 
4.7 Antibiotics 
Penicillin Streptomycin (Invitrogen GmbH; Darmstadt, GE) 
4.8 Antibodies 
Primary: P44/42 MAPK (ERK 1/2) rabbit Ab (Cell Signaling Technology, Inc.; 
Frankfurt am Main, GE) 
Phospho-P44/42 MAPK (p-ERK 1/2) rabbit Ab (Cell Signaling Technology, 
Inc.; Frankfurt am Main, GE) 
Biotin Rat anti-mouse Ly-6G and Ly-6C clone RB6-8C5 (Gr-1) (BD 
Biosciences, Franklin Lakes, NJ, USA) 
Rat IgG Biotinylated Ab (Vector Laboratories, Inc.; Burlingame, CA, USA) 
 
Secondary: Anti-Rabbit IgG (whole molecule)-Peroxidase (Sigma-Aldrich Chemie 
GmbH; Steinheim, GE) 
4.9 Kits 
ABC Kit – Vercastain, Peroxidase standard (Vector Laboratories, Inc.; Burlingame, CA, 
USA) 
DAB Kit – Peroxidase substrate kit (Vector Laboratories, Inc.; Burlingame, CA, USA) 
Immobilon Western, Chemimuminescent HRP Substrate (Millipore Corporation; 
Billerica, USA) 
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4.10 Buffers 
Table 1. Buffers for western blot 
Leammli buffer 2x: 4% SDS 
 2% 2-mercaptoethanol or 200 mM DTT 
 20% glycerol 
 0.004% bromophenol blue 
 0.5 M Tris HCl pH 6.8 
 add ddH2O 
 
Lysis buffer (RIPA buffer): 50 mM Tris HCl pH 7.4 
 150 mM NaCl 
 1% NP-40 
 0.5% sodium desossicolate 
 0.1% SDS 
 add ddH2O 
Just before use add:  1 protease inhibitor coctail tablet 
 1 phosphatase inhibitor coctail tablet 
 2 mM sodium orthovanadate 
   
Running buffer: 25 mM Tris HCl pH 8.3 
 190 mM glycine 
 0.1% SDS 
 add ddH2O 
  
TBST: 0.1% Tween 20 
 add TBS 
     
Transfer buffer: 25 mM Tris HCl pH 8.3 
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 190 mM glycine 
 0.1% SDS 
 20% methanol 
 add ddH2O 
 
Mild stripping buffer: 200 mM glycine 
 0.1% SDS 
 1% Tween 20 
 adjust to pH 2.2 with HCl 
 add ddH2O 
 
Table 2. Buffers for staining       
PBS/ H2O2/ CH3OH: 1% H2O2 
 add PBS + 99% methanol (1:1) 
    
PBS/ NHS: 10% NHS 
 add PBS 
PBST: 0.1% Triton 
 add PBS 
4.11 Solutions    
Table 1. Gels for western blot 
Separating gel 10%: 10% acryl-bisacrylamide mix 
 400 mM HCl pH 8.8 
 0.1% SDS 
 0.1% APS 
 0.04% TEMED 
 add ddH2O 
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Stacking gel 4 %: 4% acryl-bisacrylamide mix 
 200 mM HCl pH 6.8 
 0.1% SDS 
 0.1% APS 
 0.1% TEMED 
 add ddH2O 
  
Table 2. Stock solutions 
TBS 10x: 24.23 g Tris 
 0.06 g NaCl 
 mix in 800 ml ddH2O 
 adjust to pH 7.6 with HCl 
 add 1000 ml ddH2O 
    
PBS 10x: 80.0 g NaCl 
 2.0 g KCl 
 18 g Na2HPO4.2H2O 
 2.4 g KH2PO4 
 adjust to pH 7.4 with HCl 
 add up 1000 ml with ddH2O 
    
Table 3. Stock solutions for western blot 
BSA (or milk) 5% solution: 5% BSA (or NFDM) 
 add TBST 
  
Ponceau Red solution: 0.2% Ponceau S 
 5% acetic acid 
 add ddH2O 
 
30 
 
Table 4. Solution for cell culture 
Enzyme solution: 0.25 mg/ml Trypsin 
 1 mg/ml Collagenase 
 0.2 mg/ml DNAse 
 add F12 + P/S 
 
F12 + 10% FBS + AraC: 10% FBS 
 5 μM AraC 
 10 ng/ml NGF 
 add F12 + P/S 
 
Percoll solutions:  
SIP 9 v/v (9 ml) Percoll 
 1 v/v (1 ml) PBS 10x 
Percoll 35% (5 ml): 1.75 ml SIP 
 3.25 ml F12 
Percoll 25% (5 ml): 1.25 ml SIP 
 3.75 ml DMEM 
 
Table 5. Solution for staining 
Mowiol solution: 2.4 g Mowiol 4-88 
 6.0 g Glycerin 
 6.0 ml ddH2O 
 12.0 ml 0.2 M Tris-HCl pH 8.5 
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4.12 Software  
Adobe Photoshop CS2 
Endnote X1 
Graph prim 5 
ImageJ 
Microsoft Office 
  
32 
 
5 METHODS 
5.1 Von Frey test 
For mechanical testing, the mice were placed individually in a small plastic cage with 
an open wire mesh bottom. The mice were acclimatized to the setup before testing 
and were unaware of the testing. Mechanical sensitivity was measured by applying 
punctuate pressure using 0.07g Von Frey filaments. The filaments were applied 
perpendicularly to the plantar surface in the middle of the mouse’s hind paw with an 
upward force just sufficient to bend the microfilament. A positive response was 
considered a paw withdrawal before the filament bending and we measured frequency 
of response out of five applications.  
5.2 DRG culture 
5.2.1 Isolation of dorsal root ganglia 
After anesthetizing the mice with CO2, the animals were decapitated and vertebral 
column was surgically exposed. 30-40 dorsal root ganglia were quickly dissected and 
placed into ice cold F12+GlutaMax medium containing 2 % Penicillin and Streptomycin 
(P/S). Subsequently, surrounding membranes, axons and meningeal residues were 
separated from actual cell bodies.  
5.2.2 Cell culture preparation 
The clean DRGs were digested with 1 ml of the enzyme solution for 30 minutes at 
37°C in agitation (thermomixer 14000 rpm) and mechanically dissociated with the 
previously coated pipette subsequently. The digestion was stopped by adding 120 μl of 
Trypsin inhibitor and 100 μl of 10% FBS. The suspension was centrifuged for 3 minutes 
at 1000 rpm.  
After centrifugation, the supernatant was removed and cells were resuspended into 
2ml F12+Glu+P/S medium with 10% FBS. The cell suspension was then carefully loaded 
on Percoll gradient (2.5 ml of 25% the upper phase and 1.5 ml of 35% the lower phase) 
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and centrifuged for 15 minutes at 1000g. Percoll gradient creates the density gradient 
that separates the cells on the basis of their size and density. The lower part of the 
supernatant (approximately 1.5 ml) and the pellet was kept and washed 2 times, first 
time with 13.5 ml F12+GlutaMax+P/S and 10% FBS and after 10 minute centrifugation 
(500g) with 9 ml F12+GlutaMax+P/S and 10% FBS, then centrifuged for 8 minutes 
(400g). The pellet was resuspended in 320 µl F12+GlutaMax+P/S and 10% FBS and 
distributed to the wells previously coated with poly-L-lysine. Firstly, 60 µl of the cell 
solution was placed in the middle of each plate and after 10 minutes the total volume 
up to 200 µl of F12+GlutaMax+P/S and 10% FBS was added.  
The cells were grown in the medium for 3 days at 37°C in a atmosphere of 5 % CO2. 
The vitality of the culture was checked every day and the medium was replaced by the 
fresh one with additional NGF (neural cells growth factors) and AraC.  
5.2.3 Treatment of the cells 
On the fourth day, the cells were refed with F12+GlutaMax+P/S culture medium 
deprived of serum. This starvation serves as a pre-treatment of the cells in order to 
lower the metabolism resulting in the increased efficacy of the response following the 
treatment. After 2 hours, the cells were treated with 2 ml of 3 µM LPI for 15 minutes.  
5.3 Western blot 
Western blot is a method widely used to detect specific proteins, which are 
separated in denatured state according to their molecular weight using SDS 
polyacrylamide gel electrophoresis (SDS-PAGE). The proteins are subsequently 
transferred onto nitrocellulose or PVDF membrane and detected by antibodies specific 
to the target protein. 
5.3.1 Samples preparation 
100 μl of complete lysis buffer together with protease and phosphatase inhibitors 
were added into the cell solution right after treatment. The DRG samples were then 
homogenized by sonicator 3 times each for 3 seconds and left for 30 minutes in ice, 
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occasionally vortexed. After complete cell lysis, the homogenate was clarified by 
centrifugation at 13000 rpm for 15 minutes at 4°C. The supernatant, corresponding to 
the cytosolic fraction was collected and the protein concentration was determined by 
Nanodrop by 260/280 nm spectrophotometry. 
Before the loading, protein samples were boiled for 5 minutes together with 
Leammli buffer, which caused denaturation of proteins. Denaturation achieves the 
linear state of proteins, so that they no longer have any secondary, tertiary or quartery 
structure and can be easily separated according to their size. After the denaturation, 
the samples were centrifuged for 1 minute at 11000 rpm. 
5.3.2 SDS-PAGE gel preparation 
SDS-PAGE gels separate proteins according to their size in the presence of electric 
current. SDS is a denaturing detergent that binds to the proteins’ positive charged 
amino acids and neutralizes them; therefore all proteins become negatively charged. 
Thus they migrate towards the positively charged electrode when placed in an electric 
field, whereas smaller molecules move faster than bigger and proteins become 
separated according to their size. 
Separation of proteins was performed by SDS-PAGE using 1 mm thick gel sandwich 
set out of 2 discontinues phases – separation gel and stacking gel. The purpose of using 
two different gels is to concentrate isolated proteins and place them to the boundary-
line so they all enter separation gel at the same time.  
To separate the proteins, 10% separating gel was used consisting of 1.5 ml of 25% 
separation buffer, 2.0 ml of 30% acrylamide/bisacrylamide mixture, 2.4 ml of ddH2O, 
100 µl of APS and 5 µl of TEMED. The polymerization of acrylamide and N,N-
methylenebisacrylamide is catalyzed by addition of ammonium persulfate (APS) and 
TEMED, therefore they were added just before casting of the gel. The gel was allowed 
to polymerize at room temperature under isopropanol level, which ensures smooth 
surface of the gel. After complete consolidation, the isopropanol was removed and 
with inserted comb, 4% stacking gel was casted onto polymerized separating gel and 
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was let polymerize. The gel consisted of 0.88 ml of 25% stacking buffer, 0.56 ml of 30% 
acrylamide/bisacrylamide mixture, 2.01 ml of ddH2O, 50 µl of APS and 5 µl of TEMED.  
5.3.3 SDS-PAGE gel electrophoresis 
After complete polymerization of the stacking gel, gels were assembled in the 
vertical electrophoresis chamber with running buffer. The comb was removed from 
the stacking gel and samples were loaded into the gel wells in desired volume together 
with 10 µl of protein molecular weight marker. The constant voltage of 120 V was used 
to conduct electrophoresis until the blue dye migrated to the bottom of the gel. 
The separation of molecules in a gel depends on the percentage of the gel, which is 
determined by the total amount of acrylamide and the amount of cross-linking agent 
(N,N-methylenebisacrylamide) present in the gel. The pore size increases with less 
amount of acrylamide. Therefore for larger protein lower percentage of acrylamide 
should be used, whereas for smaller protein higher percentage of acrylamide is 
preferred. 
5.3.4 Protein electrotransfer 
After protein separation by SDS-PAGE electrophoresis, proteins were transferred 
from the gel onto previously wetted nitrocellulose membrane in order to make them 
accessible to detection. The membrane was placed on top of the gel and sandwiched 
by filter papers and sponges ensuring no air bubbles between the layers. This blotting 
sandwich consisting of sponge-paper-gel-membrane-paper-sponge was assembled in 
the transfer chamber in the correct orientation, so that the membrane is on the side 
close to the anode. Transfer was performed at constant amperage of 300 mA for 2 
hours in the presence of the cold transfer buffer and 100% methanol.  
This electroblotting method uses an electric current to migrate the negatively-
charged proteins from the gel towards the positively-charged electrode into PVDF or 
nitrocellulose membrane, where they bind on basis of hydrophobic and charge 
interactions. 
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In order to check the effectiveness of the transfer, the membrane was stained by 
Ponceau Red solution for 5 minutes and rinsed with ddH2O until the bands became 
well-defined. After registering, the membrane was distained completely by repeated 
washing with TBST. 
5.3.5 Blocking 
The membrane was incubated in the blocking solution consisting of 5% non-fat dry 
milk (NFDM) in TBST for 1 hour at room temperature under agitation in order to 
reduce unspecific binding of the antibodies.   
5.3.6 Incubation with primary antibody 
Detection with antibodies is a sensitive method based on the normal immune 
reaction components, when antibodies bind to the specific antigen. Membranes were 
incubated with monoclonal rabbit antibodies detecting ERK 1/2 and phosphorylated 
ERK 1/2 (p-ERK 1/2) both at a dilution of 1:500 in 5% BSA in TBST after previously 
tested most appropriate dilution. The membrane was incubated with antibody solution 
overnight at 4°C under gentle agitation. In between the two detections, the 
membranes were stripped in mild stripping buffer.  
5.3.7 Incubation with secondary antibody 
After washing of the membranes 3 times 10 minutes with TBST at room 
temperature to remove unbound primary antibody, the membranes were incubated 
with a specific horseradish peroxidase-conjugated (HRP-conjugated) anti-rabbit IgG 
secondary antibody at a dilution of 1:1000 in 5% NFDM in TBST for 1 hour at room 
temperature and washed again 3 times 10 minutes with TBST at room temperature. 
Secondary antibody is directed against the primary antibody and is usually linked to 
an enzyme, such as horseradish peroxidase catalyzing reaction, which products provide 
detectable luminescence.  
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5.3.8 Development 
Enhanced Chemiluminescence (ECL) detection system was used to visualize the 
bands of proteins, where luminol is used as a substrate, which is converted by 
horseradish peroxidase to a light releasing substance. Following manufacturer’s 
instructions for HRP substrate preparation, a sensitive sheet of photographic film was 
placed on the membrane surface and film was developed using automated x-ray film 
processor to detect and fix the signal. Dark bands corresponding to the detected 
protein of interest appear on the developed film, which density is in proportion of the 
amount of protein. Densitometric analysis of bands was carried out using ImageJ 
software. Absolute band intensity values of phosphorylated protein bands (p-ERK 1/2) 
were then divided by those for total protein (ERK 1/2) to generate a ratio. Band 
densities in different lanes were then compared providing information on relative 
abundance of the protein of interest. 
5.3.9 Membrane stripping 
In order to detect the protein with another antibody, the combination of detergent 
and heat was used to disrupt the antigen-antibody interaction. Therefore, membranes 
were incubated in a mild stripping buffer for 30 minutes at 50°C in agitation. Three 
times washing with TBST was necessary before blocking and incubating with another 
antibody.  
5.4 Vascular permeability assay 
Plasma extravasation is one of the characteristic symptoms associated with 
inflammation. It is a process in which proteins and cells leak out of postcapillary 
venules accompanied by fluid. Evans blue dye has a very high affinity for serum 
albumin, which is often used to quantitatively assess the extent of extravasation as a 
symptom of inflammation.  
The animals were anesthetized with a sleeping mix injected intraperitoneally 
depending on the body weight of the mouse (3 µl/g). The 1% Evans blue in PBS was 
subsequently administered intraorbitally in the total volume of 50 µl for each mouse. 5 
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minutes after the animal turned blue, 20 µl of 3 µM LPI was injected intraplantary into 
one hind paw, whereas contralateral paw was used as a control. PBS injection was 
used as a negative and 1 µg of histamine injection as a positive control in the test 
results evaluation. After 10 minutes of different treatments, the mice were killed by 
cervical dislocation and tissue samples containing a 12 mm2 paw skin were incubated 
in 200 µl of formamide at 55°C for 48 hours. Afterwards, the amount of Evans blue was 
determined spectrophotometrically at the maximum absorption of 595 nm and 
expressed as a number of nanograms per 1 mm2 of the skin.  
5.5 Staining 
5.5.1 Hematoxylin and eosin staining 
5.5.1.1 Treatment of animals and preparation for staining 
After the 30 seconds isofluran anesthesia, the animals were intraplantary injected 
with 3 µM, 300 µM LPI, CFA and PBS into one hind paw. The animals were 
anesthetized with CO2 after 10 minutes, fixed on the cork plate and after median 
thoracotomy the heart was perfused with 20 ml of PBS and 20 ml of 4% PFA 
subsequently in order to fix the tissue proteins. The skin of the total area of 12 mm2 
was then removed from each paw and put in 4% PFA solution, whereas the 
contralateral paws were used as a control. 
5.5.1.2 Cutting 
The paw skin was stored in 30% sucrose overnight before the cutting was 
performed. Cryomicrotom set at -25°C and thickness of 25 µm was used to cut the skin 
tissue. The paw skin was fixed in the correct orientation with the help of tissue freezing 
medium. The sections were collected on previously coated polysine (0.1 %) slides and 
stored at -20°C. 
5.5.1.3 Staining 
Hematoxylin and eosin staining (H and E staining) is a widely used staining method 
in histology. This method enables differentiation of the structures of tissue and 
determines the changes in normal or inflamed or other pathologicaly changed 
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structures. The actual staining consists of two main parts - nuclear staining provided by 
hematoxylin, which stains the nuclei in dark blue and cytoplasm staining, which is 
performed by xanthenes dye and it stains the cytoplasm in red. 
Slides with the cryosections were dried for 30 minutes at room temperature. As 
non-paraffin sections were used, the deparaffination and rehydration was not 
necessary. We proceeded with 1% acidic acid in ddH2O to incubate the slides for 20 
seconds. Then hematoxylin solution was used for 4 minutes, which was subsequently 
washed out from slides with warm tapped water for 2 minutes. The intensity of 
staining was controlled under microscope and the time was adjusted for optimal 
visibility. After hematoxylin staining, the eosin solution was poured for 5 seconds on 
each slide and 1% acidic acid in ddH2O afterwards. The sections were dehydrated with 
70%, 80%, 95% and 99% ethanol series for 2 minutes and with xylol at the end 2 times 
for 5 minutes. The dried slides were embedded with coverslips using Mowiol ensuring 
no bubbles. Images were obtained using Leica microscope. 
5.5.2 DAB staining 
The slides with cryosections were dried for 30 minutes at room temperature. 1% 
H2O2 in PBS/Methanol was used for 15 minutes at room temperature in order to block 
endogenous peroxidise activity. After washing the slides for 10 minutes with 0.2% 
PBST, the unspecific binding was blocked with 10% normal horse serum in PBS 
(NHS/PBS) for 40 minutes at room temperature. The sections were then incubated 
with biotinylated anti Gr-1 antibody in a dilution of 1:500 in blocking solution overnight 
at room temperature protected from light. Rat IgG bitotinylated antibody in a dilution 
of 1:200 in blocking solution was used to incubate the negative control slides. 
The following day the slides were rinsed 2 times for 10 minutes with 10% NHS and 
10 minutes in PBS and afterwards they were incubated with the ABC complex prepared 
following manufacturer’s instructions by mixing 200 µl of PBS, 4 µl of reagent A and 4 
µl of reagent B for each slide. After 30 minutes of incubation, the slides were washed 3 
times for 10 minutes with PBS. 500 µl of ddH2O, 10 µl of buffer stock solution, 20 µl of 
DAB and 10 µl of H2O2 were used to prepare the DAB solution. Afterwards, this 
solution was applied on the slides whereas the intensity of staining was controlled 
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under the microscope until the sections became dark. After achieving sufficient 
staining, the reaction was stopped by applying ddH2O on each slide. The dried slides 
were embedded with coverslips using Mowiol. Images were obtained using Leica 
microscope. 
5.5.3 Toluidine blue staining 
Toluidine blue staining technique is a method used to visualize myelin-associated 
glycoprotein in order to investigate the peripheral nerve morphology or pathological 
changes associated with demyelination. Toluidine blue solution stains myelin sheaths 
bluish purple and neuronal nuclei light blue with dark granules of chromatin. 
5.5.3.1 Treatment of animals and preparation for staining 
The animals were anesthetized with a sleeping mix injected intraperitoneally 
depending on the body weight of mouse (3 µl/g). The sciatic nerve of the right hind 
limb was surgically exposed at the level of the high thigh through a small incision and 
1 µl of 3 µM, 300 µM LPI or PBS was subsequently injected with into the sciatic nerve. 
The incision was sutured and mice were allowed to recover. After 24 hours, the 
animals were asphyxiated with CO2, fixed on the cork plate and after median 
thoracotomy, the heart was perfused with 20 ml of PBS and 20 ml of 4% PFA 
subsequently in order to fix the tissue proteins. Both the right and left sciatic nerves 
were then removed and stored in 4% PFA. 
5.5.3.2 Cutting and staining 
2 µm thin sections were cut and stained with alkaline toluidine blue. At first, the 
sections were deparaffinized at 65°C in an oven, followed by 15 minute treatment with 
xylene. Subsequently, the sections were hydrated using xylene for 5 minutes twice and 
in 100%, 90%, 70% and 50%  alcohol series for 2 minutes in each dilution. The sections 
were stained for 5 minutes with previously prepared toluidine blue staining solution 
consisting of 1g toluidine blue in 100 ml of 1% sodium borate. They were then washed 
in water and dehydrated with 70%, 90% and 100% alcohol series for 30 seconds, 
treated with xylene for 30 seconds, air-dried and mounted with mowiol. The stained 
sections were observed and images were obtained using  Leica light microscope. 
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5.6 Statistical analysis 
All data are presented as mean ± SEM. Statistical comparison of two groups was 
provided using two-tailed student t-test whereas multiple groups comparison by using 
one way analysis of variance (ANOVA) followed by Neuman-Keuls test. P<0.05 was 
considered to be statistically significant difference. 
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6 RESULTS 
6.1 LPI induced ERK activation in DRG culture 
We first examined the effect of LPI on ERK phosphorylation in the DRG culture, 
since ERK is a major downstream target of various intracellular signaling pathways. 
Also, LPI has been suggested to activate ERK 1/2 signaling in GPR55 expressing HEK293 
cells (Oka et al. 2007). Although GPR55 is expressed in sensory neurons of the dorsal 
root ganglion (Lauckner et al. 2008), it is not very clear if GPR55 ligand LPI can activate 
its downstream signaling cascades also in the DRG neurons. Thus, we examined 
whether the expression of ERK 1/2 and of its active form phospho-ERK would be 
altered after LPI treatment in DRG neurons. 
Western blot experiments were performed in order to detect changes in the 
expression of ERK and p-ERK proteins in neuron-enriched DRG culture 15 minutes after 
3 µM LPI treatment. After separation of the proteins using the SDS-PAGE 
electrophoresis, proteins were blotted onto a nitrocellulose membrane and p-ERK 1/2 
was detected using phospho-specific antibody. Subsequently, blots were stripped and 
re-probed with the antibody detecting both phosphorylated and non-phosphorylated 
forms of ERK 1/2. The p-ERK signal intensity of the DRG culture treated with 3 µM LPI 
was compared with signal intensity of the DRG culture treated with the vehicle. 
 
Figure 6.1.1. Western blot of protein lysates from neuron-enriched DRG culture showing ERK 
phosphorylation 15 minutes after application of LPI.  
- 55 
- 55 
ERK1/2  
Vehicle    3uM LPI 
    15 min  
p-ERK1/2  
43 
 
                     
 
Figure 6.1.2. Quantification of ERK phosphorylation in neuron enriched DRG culture 15 
minutes after application of LPI. The histograms quantify the changes of anti-p-ERK 1/2 
antibody signals of vehicle and 3 µM LPI-treated DRG culture, showing an increase of 
phosphorylation of ERK 1/2 15 minutes after 3 µM LPI treatment. Changes were measured 
with optical density values expressed in A.U. 
 
The western blot analysis revealed that stimulation of neuron-enriched DRG culture 
with 3 µM LPI increases the phosphorylation of ERK 1/2 15 minutes after treatment 
compared with vehicle treated DRG cultures under equal protein loading conditions 
assessed with total ERK 1/2 as demonstrated by western blots (Figure 6.1.1.) and its 
quantification (Figure 6.1.2). 
This experiment indicates that LPI can directly activate neurons of DRGs. This 
observation also led us to an important question; whether LPI released from the 
cancer tissue could cause the activation of nociceptive terminals in the cancer 
environment and therefore lead to cancer induced pain. 
 6.2 LPI induced Hyperalgesia
In order to test our hypothesis that
from the tumor environment can possibly ev
injected LPI into the plantar surface of the hind paw of the mice. A single int
injection of LPI led to long lasting mechanical hyperalgesia in a dose dependent 
manner without eliciting any swelling or reddening
6.1). On the other hand, injection of vehicle alone d
change in the response frequency. 
 
Figure 6.
 
An upward and leftward shift in the above 
hypersensitivity to mechanical force applied using von Frey filament to the hind paw of 
the animal. 
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 6.3 Hematoxylin and eosin staining
Although there were no obvious inflammatory responses like reddening or 
present after LPI injection, we performed H and E staining to 
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 6.4 Neutrophil invasion 
To further characterize the accurate inflammatory state after LPI treatment, we 
labeled neutrophils of the paw skin sections 
same and we stained them using DAB system.
neutrophils after the application of 300 
groups (3 µM LPI, 100 nM
was found in the skin 24 hours after CFA 
 
 
Figure 6.4.1. Representative sections 
  
Stained invaded cells were subsequently counted manually and quantified using 
Graph prim 5 software in order to 
which have traversed into the injected area
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using Gr-1 antibody, a marker for the 
 We found very few infiltrated 
µm LPI and hardly any neutrophils in other 
 LPI and vehicle). In contrast, large amount of neutrophils 
injection (Figure 6.4.1). 
of DAB stained paw skin. Magnification 20
accurately determine the number of 
 (Figure 6.4.2.). 
 
× 
neutrophils, 
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Figure 6.4.2. Quantitative analysis of neutrophil infiltration. * P < 0.001  
 
The above H and E and Gr-1 staining clearly suggest that LPI does not mediate 
mechanical hypersensitivity by inducing inflammation.  
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6.5 Extravasation 
The vascular events associated with inflammation could involve changes in blood 
flow and alterations in permeability resulting in oedema and possibly also lead to the 
mechanical hypersensitivity. Thus, we determined the extend of extravasation after 
intraplantar injection of PBS, 3 µM LPI and 1 µg of histamine using Evans blue dye test. 
 
 
 
 
We observed that neither treating mice with 3 µM LPI nor with the vehicle led to 
accumulation of systemically injected Evans blue dye in the area of the skin. In 
contrast, injection of 1 µg of histamine led to a strong plasma extravasation. This 
experiment also indicates that LPI does not bring about the mechanical 
hypersensitivity by plasma extravasation (neurogenic inflammation). 
Figure 6.5. Vascular permeability changes associated with intraplantar injection of PBS,        
3 µM LPI and histamine. *P< 0.001, n.s P = 0.5631 
49 
 
6.6 Demyelination 
It has been reported, that neuropathic pain is associated with aberrant 
demyelination (Gillespie et al. 2000). In order to investigate the mechanism, through 
which LPI possibly mediates its pronociceptive activity, we examined the myelination 
status of mice sciatic nerves after intranerval LPI injection using Toluidine blue staining 
and light microscopic analysis (Figure 6.6.).  
 
 
 
 
 
 
 
 
 
Magnification? 
 
According to our observation, treatment with LPI was not followed by 
demyelination of the injected sciatic nerves. This suggests that LPI does not elicit 
mechanical hypersensitivity by affecting the myelination of sensory  neurons. 
  
 
Fi ure 6.6. Representative sections of TB stained sciatic nerves. Magnification 20× 
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7 DISCUSSION 
GPR55 has been recently identified as a novel cannabinoid receptor with atypical 
responsiveness to cannabinoid ligands (Ryberg et al. 2007; Kapur et al. 2009). Recent 
study with GPR55 expressing HEK293 cells has also shown that GPR55 is activated by 
the endogenous lipid signaling molecule LPI (Oka et al. 2007) and that it is  expressed 
among other tissues also on sensory neurons (Lauckner et al. 2008). In addition, LPI is 
known to be produced by variety of cancer tissues (Falasca et al. 1998), suggesting the 
hypothesis that LPI might be one of the factors corresponding to the development of 
neuropathic cancer pain. 
One of the pathways involved in mitogenic signaling induced by various GPCRs is 
the pathway of extracellular-regulated protein kinase (ERK), which belongs to the 
mitogen-activated protein kinase (MAPK) signaling cascades (Cargnello and Roux). 
Stimulation of GPR55 by LPI is known to induce rapid phosphorylation of ERK 1/2, 
which was revealed at the study using HEK293 transfected cells (Henstridge et al.; Oka 
et al. 2007). In agreement with this study, using WB method we investigated that LPI 
treatment leads to activation of ERK signaling pathway in DRG cell culture (Figure 
6.1.1.). This suggests that LPI can directly activate sensory neurons in vitro, which is 
possibly one of the pathways through which LPI exerts its properties on sensory 
neurons in vivo.  
In order to establish the physiological or pathophysiological function of LPI, further 
investigation needed to be performed, especially due to very limited information 
providing the ability of LPI to induce pain in vivo. Research performed by Staton et al. 
(2008) revealed that GPR55 signaling pathway plays a role in mechanical hyperalgesia 
associated with inflammatory and neuropathic pain, where they demonstrated that 
GPR55 deficient mice failed to develop inflammatory mechanical hyperalgesia 
following intraplantar administration of CFA up to 14 days post-injection. Following 
this study we investigated that intraplantar administration of LPI to the wild-type mice 
leads to long lasting mechanical hyperalgesia in a dose dependent manner without 
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eliciting any signs of inflammation (Figure 6.2.), which clearly supports previously 
assumed pronociceptive properties of LPI.  
The cardinal signs of inflammation involve heat (calor), redness (rubor), swelling 
(tumor) and pain (dolor), often accompanied by loss of function (function laesa) 
(Kumar et al. 2010). Even though we observed no signs of inflammation after 
intraplantar LPI injection in previous experiment, the study of Staton et al. (2008) 
showed the involvement of GPR55 signaling pathway in inflammatory pain  and thus 
we performed H and E staining of injected paw skin in order to visualize possible 
inflammatory changes on the cellular level following LPI injection. Our observation led 
us to a conclusion that intraplantar LPI administration does not elicit any visual 
pathological changes in the skin structure with any massive cell invasion nor 
vasodilatation (Figure 6.3.). 
The major cell types producing substances that contribute to the acute 
inflammatory reaction are platelets, neutrophils, monocytes/macrophages and mast 
cells, while neutrophils constitute the predominant cell type in the early inflammatory 
reaction (Kumar et al. 2010). Thus, we used Gr-1 antibody to specifically label 
neutrophils and DAB staining of the histological sections of paw skin to visualize the 
cellular inflammatory changes following intraplantar LPI administration (Figure 6.4.1.). 
Quantitative analysis of the present number of cells revealed non-significant increase 
of neutrophils in the injected area (Figure 6.4.2.), which also supports our previous 
experiment observation.   
As previously mentioned, acute inflammatory reaction is associated with massive 
vasodilatation leading to an increase in blood flow reflected by the heat and redness of 
the tissue. The vasodilatation is followed by alterations in microvascular permeability 
resulting in leakage of plasma from the vasculature (Kumar et al. 2010). In order to 
assess the microvascular permeability changes after LPI administration we performed 
vascular permeability assay which revealed no aberrant extravasation after LPI 
administration (Figure 6.5.). 
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All these observations concerning the experiments investigating the mechanism of 
action of LPI indicate that LPI does not mediate its pronociceptive effect by inducing 
inflammation. 
It has been reported that demyelination and subsequent physical contact of nerve 
fibers might be one of the mechanisms responsible for neuropathic pain (Osterberg et 
al. 2005). In addition, lysophosphatidic acid (LPA), a closely related lysophospholipid of 
LPI can cause demyelination and neuropathic pain in mice and blocking of the LPA 
signaling through its receptor was shown to reverse the neuropathic pain (Inoue et al. 
2004). It has also been described that the enzyme autotaxin converting various 
lysophospholipids into LPA is present in the plasma (Inoue et al. 2008). These studies 
raise the possibility that injected LPI might be in vivo converted into LPA, leading to 
demyelination and mechanical hypersensitivity. Thus, we investigated the patho-
physiological changes in myelinated axons of sciatic nerve induced by LPI injection 
using Toluidine blue staining method. Observation of visualized myelinated fibers 
clearly indicated that no aberrant demyelination is associated with LPI injection (Figure 
6.6.), which does not support previous hypothesis about LPI converting into LPA in 
vivo. However, blocking of LPA receptor downstream and subsequent LPI stimulation 
can also help to reveal whether LPI does not exert its pronociceptive effect through 
the conversion to LPA. 
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8 CONCLUSION 
Although LPI and its receptor GPR55 is expressed in the nervous system, very little is 
known about their function in vivo. We found that LPI can directly activate nociceptors 
by activating ERK signaling pathway in vitro and that LPI injected in the periphery leads 
to a mechanical hypersensitivity in mice in a dose dependent manner. In addition, the 
results of this study demonstrate that LPI does not elicit any inflammation, 
demyelination or extravasation.  
Selective blocking of the LPI-GPR55 pathway may represent a novel perspective in 
treatment and prevention not only of cancer and non-cancer pain but it may also 
contribute to reducing tumor growth and metastasis. Therefore, the elucidation of 
physiological functions of GPR55 and its endogenous ligand LPI is likely to provide 
better treatment options in future.    
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9 ABBREVIATIONS 
A.U.   Arbitrary unit 
Ab   Antibody 
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  
APS    Ammonium persulfate 
AraC   Cytarabine 
BSA    Bovine serum albumin 
cAMP   Cyclic adenosine monophosphate 
CB   Cannabinoid receptor 
CBD   Cannabidiol 
CBN   Cannabinol 
CFA   Complete Freund’s adjuvant 
CNS   Central nervous system 
DAB    Diaminobenzidine 
ddH2O   Double distilled water 
DMEM   Dulbecco´s modified eagle medium 
DNAse   Deoxyribonuclease 
DPBS    Dulbecco´s phosphate buffered saline 
DRG    Dorsal root ganglia 
DTT    Dithiotreitol 
ECL    Enhanced Chemiluminescence 
ERK   Extracellular signal regulated kinase 
FBS    Fetal bovine serum 
GPCR    G-protein-coupled receptor 
GPR55   G-protein-coupled receptor 55 
H and E  Hematoxylin and eosin 
HEK cells  Human embryonic kidney cells 
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HRP    Horseradish peroxidase 
IASP    International Association for the Study of Pain 
IgG   Immunoglobulin G 
LPA   Lysophosphatidyl acid 
LPI   Lysophosphatidylinositol 
MAPK   Mitogen activated protein kinase 
mGluR   Metabotropic glutamate receptor 
NFAT    Nuclear factor of activated T cells 
NFDM    Non-fat dry milk 
NGF    Nerve growth factor 
NHS    Normal horse serum 
NMDA   N-methyl-D-aspartate  
PBS   Phosphate buffered saline 
PBST    Phosphate buffered saline with Tween-20 
P/S    Penicillin/Streptomycin 
PFA    Paraformaldehyde 
PVDF    Polyvinylidene difluoride 
rpm   Revolutions per minute 
SDS    Sodium dodecyl sulfate 
SDS-PAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SIP    Stock isotonic Percoll 
TB   Toluidine blue 
TBS    Tris-buffered saline 
TBST    Tris-buffered saline with Tween-20 
TEMED   Tetramethylethylenediamine 
THC    Δ9-tetrahydrocannabinol 
Tris   Tris-(hydroxymethyl)-aminomethan 
WB    Western blot 
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